1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6EC78BF724235895A002585DF00483FDE
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-maximizing-impact-analytics-insights-teams-across-biopharma-organization-optimizing-analytics-capabilities?opendocument
18
19opendocument
203.237.254.197
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Market Research, Analytics and Forecasting » Analytics

Maximizing the Impact of Analytics and Insights Teams across the Biopharma Organization: Optimizing Analytics Capabilities

ID: 5642


Features:

17 Info Graphics

18 Data Graphics

820+ Metrics

13 Narratives


Pages/Slides: 41


Published: 2020


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Maximizing the Impact of Analytics and Insights Teams across the Biopharma Organization: Optimizing Analytics Capabilities”

STUDY OVERVIEW

Biopharma organizations are constantly striving to ensure that their analytics capabilities are keeping pace with a marketplace that is driven by rapid advances in technology and analytic methodologies.

Best Practices, LLC undertook this benchmarking research to help the Analytics & Insights (A&I) team within biopharma companies leverage their analytics and talent to provide effective strategic consultation, focus resources, optimize analytics capabilities, and scale successes.

KEY TOPICS

  • High-value analytics, methodologies, platforms and outsourcing approaches
  • Streamlining market research via analytics


KEY METRICS
  • What analytic methodologies is your Analytics & Insights group currently using, and for what operational purposes?
  • How valuable are each of the listed types of analytics for informing brand, HEOR and other key internal partner teams and driving measurable results in the market?
  • Where are each of the listed analytics activities conducted for your organization?
  • Have you used analytics to replace any of the listed market research study types?
  • What platforms does your organization currently utilize for analytics and for reporting?

SAMPLE KEY FINDINGS
  • A&I teams use many analytic methodologies to fuel commercial insights - but few to support corporate, HEOR and medical:
    • Methodologies used: 50-90% use advanced methodologies to support commercial clients: visualization, forecasting, data mining, AI, conjoint and sentiment analysis, and regression. These are used by 25% or fewer to support other internal clients (HEOR, corporate, medical) however. A majority of A&I teams do not use predictive analytics, simulation or pattern matching methodologies for any clients whatsoever.
METHODOLOGY

Best Practices, LLC engaged 44 Analytics and Insights professionals from 38 leading biopharma organizations in this research through a benchmark survey. Data in this study are segmented by mid vs. large pharma companies. Deep-dive interviews were conducted with selected benchmark participants to provide further insights. Over 85% of research participants serve at the director level or above.


Industries Profiled:
Medical Device; Biotech; Biopharmaceutical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Research; Consulting; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alcon; Alkermes; Amgen; Arena Pharmaceuticals; AstraZeneca; Atara Biotherapeutics; Bayer; Bio-Rad Laboratories; Inc.; Biotest AG; Biotronik; Boehringer Ingelheim; B.Braun; Dermira; Edwards Lifesciences; GlaxoSmithKline ; Grünenthal; Janssen; Klosterfrau Healthcare Group; LEO Pharma; Lonza Inc.; MEDiSTRAVA; Merck; Merck Sharp & Dohme; Mitsubishi Tanabe Pharma; Momenta; Novartis; Pfizer; Qiagen; REGENXBIO Inc.; Sanofi; Santen; Scilex Pharmaceuticals; Seqirus; Servier; Sunovion; Takeda Pharmaceuticals; UCB Pharma; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.